LONDON, June 06, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation, announced today that the US Patent Trial and Appeal Board (PTAB) reaffirmed decisions to uphold ‘257 Patent and ‘259 Patent, key patents covering COMP360 crystalline psilocybin polymorph A, the polymorph being used in the…


Previous articleCedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed’s Phase 2B study evaluating MM-120
Next articleAre You Attending PS2023? Here’s Where to Find Psychedelics Today in Denver